Literature DB >> 33511018

Biomimetic Anti-PD-1 Peptide-Loaded 2D FePSe3 Nanosheets for Efficient Photothermal and Enhanced Immune Therapy with Multimodal MR/PA/Thermal Imaging.

Xueyang Fang1, Xianlin Wu2,3, Zhendong Li4, Lijun Jiang1, Wai-Sum Lo1, Guanmao Chen5, Yanjuan Gu1, Wing-Tak Wong1.   

Abstract

Metal phosphorous trichalcogenides (MPX3) are novel 2D nanomaterials that have recently been exploited as efficient photothermal-chemodynamic agents for cancer therapy. As a representative MPX3, FePSe3 has the potential to be developed as magnetic resonance imaging (MRI) and photoacoustic imaging (PAI) agents due to the composition of Fe and the previously revealed PA signal. Here, a FePSe3-based theranostic agent, FePSe3@APP@CCM, loaded with anti-PD-1 peptide (APP) as the inner component and CT26 cancer cell membrane (CCM) as the outer shell is reported, which acts as a multifunctional agent for MR and PA imaging and photothermal and immunotherapy against cancer. FePSe3@APP@CCM induces highly efficient tumor ablation and suppresses tumor growth by photothermal therapy under near-infrared laser excitation, which further activates immune responses. Moreover, APP blocks the PD-1/PD-L1 pathway to activate cytotoxic T cells, causing strong anticancer immunity. The combined therapy significantly prolongs the lifespan of experimental mice. The multimodal imaging and synergistic therapeutic effects of PTT and its triggered immune responses and APP-related immunotherapy are clearly demonstrated by in vitro and in vivo experiments. This work demonstrates the potential of MPX3-based biomaterials as novel theranostic agents.
© 2020 The Authors. Published by Wiley‐VCH GmbH.

Entities:  

Keywords:  FePSe3 nanosheets; PD‐1 blockade; cancer photothermal–immune therapy; metal phosphorus trichalcogenides; multimodal imaging

Year:  2020        PMID: 33511018      PMCID: PMC7816711          DOI: 10.1002/advs.202003041

Source DB:  PubMed          Journal:  Adv Sci (Weinh)        ISSN: 2198-3844            Impact factor:   16.806


  46 in total

1.  First Measurement of the Form Factors in D_{s}^{+}→K^{0}e^{+}ν_{e} and D_{s}^{+}→K^{*0}e^{+}ν_{e} Decays.

Authors:  M Ablikim; M N Achasov; S Ahmed; M Albrecht; M Alekseev; A Amoroso; F F An; Q An; Y Bai; O Bakina; R Baldini Ferroli; Y Ban; K Begzsuren; D W Bennett; J V Bennett; N Berger; M Bertani; D Bettoni; F Bianchi; E Boger; I Boyko; R A Briere; H Cai; X Cai; A Calcaterra; G F Cao; S A Cetin; J Chai; J F Chang; W L Chang; G Chelkov; G Chen; H S Chen; J C Chen; M L Chen; P L Chen; S J Chen; X R Chen; Y B Chen; W Cheng; X K Chu; G Cibinetto; F Cossio; H L Dai; J P Dai; A Dbeyssi; D Dedovich; Z Y Deng; A Denig; I Denysenko; M Destefanis; F De Mori; Y Ding; C Dong; J Dong; L Y Dong; M Y Dong; Z L Dou; S X Du; P F Duan; J Fang; S S Fang; Y Fang; R Farinelli; L Fava; S Fegan; F Feldbauer; G Felici; C Q Feng; E Fioravanti; M Fritsch; C D Fu; Q Gao; X L Gao; Y Gao; Y G Gao; Z Gao; B Garillon; I Garzia; A Gilman; K Goetzen; L Gong; W X Gong; W Gradl; M Greco; L M Gu; M H Gu; Y T Gu; A Q Guo; L B Guo; R P Guo; Y P Guo; A Guskov; Z Haddadi; S Han; X Q Hao; F A Harris; K L He; X Q He; F H Heinsius; T Held; Y K Heng; Z L Hou; H M Hu; J F Hu; T Hu; Y Hu; G S Huang; J S Huang; X T Huang; X Z Huang; Z L Huang; T Hussain; W Ikegami Andersson; M Irshad; Q Ji; Q P Ji; X B Ji; X L Ji; X S Jiang; X Y Jiang; J B Jiao; Z Jiao; D P Jin; S Jin; Y Jin; T Johansson; A Julin; N Kalantar-Nayestanaki; X S Kang; M Kavatsyuk; B C Ke; I K Keshk; T Khan; A Khoukaz; P Kiese; R Kiuchi; R Kliemt; L Koch; O B Kolcu; B Kopf; M Kornicer; M Kuemmel; M Kuessner; A Kupsc; M Kurth; W Kühn; J S Lange; P Larin; L Lavezzi; S Leiber; H Leithoff; C Li; Cheng Li; D M Li; F Li; F Y Li; G Li; H B Li; H J Li; J C Li; J W Li; K J Li; Kang Li; Ke Li; Lei Li; P L Li; P R Li; Q Y Li; T Li; W D Li; W G Li; X L Li; X N Li; X Q Li; Z B Li; H Liang; Y F Liang; Y T Liang; G R Liao; L Z Liao; J Libby; C X Lin; D X Lin; B Liu; B J Liu; C X Liu; D Liu; D Y Liu; F H Liu; Fang Liu; Feng Liu; H B Liu; H L Liu; H M Liu; Huanhuan Liu; Huihui Liu; J B Liu; J Y Liu; K Y Liu; Ke Liu; L D Liu; Q Liu; S B Liu; X Liu; Y B Liu; Z A Liu; Zhiqing Liu; Y F Long; X C Lou; H J Lu; J G Lu; Y Lu; Y P Lu; C L Luo; M X Luo; T Luo; X L Luo; S Lusso; X R Lyu; F C Ma; H L Ma; L L Ma; M M Ma; Q M Ma; X N Ma; X Y Ma; Y M Ma; F E Maas; M Maggiora; S Maldaner; Q A Malik; A Mangoni; Y J Mao; Z P Mao; S Marcello; Z X Meng; J G Messchendorp; G Mezzadri; J Min; T J Min; R E Mitchell; X H Mo; Y J Mo; C Morales Morales; N Yu Muchnoi; H Muramatsu; A Mustafa; S Nakhoul; Y Nefedov; F Nerling; I B Nikolaev; Z Ning; S Nisar; S L Niu; X Y Niu; S L Olsen; Q Ouyang; S Pacetti; Y Pan; M Papenbrock; P Patteri; M Pelizaeus; J Pellegrino; H P Peng; Z Y Peng; K Peters; J Pettersson; J L Ping; R G Ping; A Pitka; R Poling; V Prasad; H R Qi; M Qi; T Y Qi; S Qian; C F Qiao; N Qin; X S Qin; Z H Qin; J F Qiu; S Q Qu; K H Rashid; C F Redmer; M Richter; M Ripka; A Rivetti; M Rolo; G Rong; Ch Rosner; A Sarantsev; M Savrié; K Schoenning; W Shan; X Y Shan; M Shao; C P Shen; P X Shen; X Y Shen; H Y Sheng; X Shi; J J Song; W M Song; X Y Song; S Sosio; C Sowa; S Spataro; G X Sun; J F Sun; L Sun; S S Sun; X H Sun; Y J Sun; Y K Sun; Y Z Sun; Z J Sun; Z T Sun; Y T Tan; C J Tang; G Y Tang; X Tang; M Tiemens; B Tsednee; I Uman; B Wang; B L Wang; C W Wang; D Wang; D Y Wang; Dan Wang; K Wang; L L Wang; L S Wang; M Wang; Meng Wang; P Wang; P L Wang; W P Wang; X F Wang; Y Wang; Y F Wang; Z Wang; Z G Wang; Z Y Wang; Zongyuan Wang; T Weber; D H Wei; P Weidenkaff; S P Wen; U Wiedner; M Wolke; L H Wu; L J Wu; Z Wu; L Xia; X Xia; Y Xia; D Xiao; Y J Xiao; Z J Xiao; Y G Xie; Y H Xie; X A Xiong; Q L Xiu; G F Xu; J J Xu; L Xu; Q J Xu; X P Xu; F Yan; L Yan; W B Yan; W C Yan; Y H Yan; H J Yang; H X Yang; L Yang; R X Yang; S L Yang; Y H Yang; Y X Yang; Yifan Yang; Z Q Yang; M Ye; M H Ye; J H Yin; Z Y You; B X Yu; C X Yu; J S Yu; J S Yu; C Z Yuan; Y Yuan; A Yuncu; A A Zafar; Y Zeng; B X Zhang; B Y Zhang; C C Zhang; D H Zhang; H H Zhang; H Y Zhang; J Zhang; J L Zhang; J Q Zhang; J W Zhang; J Y Zhang; J Z Zhang; K Zhang; L Zhang; S F Zhang; T J Zhang; X Y Zhang; Y Zhang; Y H Zhang; Y T Zhang; Yang Zhang; Yao Zhang; Yu Zhang; Z H Zhang; Z P Zhang; Z Y Zhang; G Zhao; J W Zhao; J Y Zhao; J Z Zhao; Lei Zhao; Ling Zhao; M G Zhao; Q Zhao; S J Zhao; T C Zhao; Y B Zhao; Z G Zhao; A Zhemchugov; B Zheng; J P Zheng; W J Zheng; Y H Zheng; B Zhong; L Zhou; Q Zhou; X Zhou; X K Zhou; X R Zhou; X Y Zhou; Xiaoyu Zhou; Xu Zhou; A N Zhu; J Zhu; J Zhu; K Zhu; K J Zhu; S Zhu; S H Zhu; X L Zhu; Y C Zhu; Y S Zhu; Z A Zhu; J Zhuang; B S Zou; J H Zou
Journal:  Phys Rev Lett       Date:  2019-02-15       Impact factor: 9.161

Review 2.  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Authors:  Kathleen M Mahoney; Gordon J Freeman; David F McDermott
Journal:  Clin Ther       Date:  2015-03-29       Impact factor: 3.393

3.  Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors.

Authors:  Mathilde Roger; Anne Clavreul; Marie-Claire Venier-Julienne; Catherine Passirani; Laurence Sindji; Paul Schiller; Claudia Montero-Menei; Philippe Menei
Journal:  Biomaterials       Date:  2010-08-05       Impact factor: 12.479

4.  Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.

Authors:  Qianglan Lu; Sun Qi; Peishan Li; Lifang Yang; Shan Yang; Yidan Wang; Yu Cheng; Yilin Song; Siyu Wang; Fengping Tan; Nan Li
Journal:  J Mater Chem B       Date:  2019-03-18       Impact factor: 6.331

5.  Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

Authors:  Sarita M Fernandez-Poma; Diego Salas-Benito; Teresa Lozano; Noelia Casares; Jose-Ignacio Riezu-Boj; Uxua Mancheño; Edurne Elizalde; Diego Alignani; Natalia Zubeldia; Itziar Otano; Enrique Conde; Pablo Sarobe; Juan Jose Lasarte; Sandra Hervas-Stubbs
Journal:  Cancer Res       Date:  2017-05-18       Impact factor: 12.701

6.  Surface modification engineering of two-dimensional titanium carbide for efficient synergistic multitherapy of breast cancer.

Authors:  Lei Bai; Wenhui Yi; Taiyang Sun; Yilong Tian; Ping Zhang; Jinhai Si; Xun Hou; Jin Hou
Journal:  J Mater Chem B       Date:  2020-08-05       Impact factor: 6.331

Review 7.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review.

Authors:  Bagher Farhood; Masoud Najafi; Keywan Mortezaee
Journal:  J Cell Physiol       Date:  2018-11-22       Impact factor: 6.384

8.  Macrophage-Mediated Delivery of Multifunctional Nanotherapeutics for Synergistic Chemo-Photothermal Therapy of Solid Tumors.

Authors:  Van Du Nguyen; Hyun-Ki Min; Deok-Ho Kim; Chang-Sei Kim; Jiwon Han; Jong-Oh Park; Eunpyo Choi
Journal:  ACS Appl Mater Interfaces       Date:  2020-02-24       Impact factor: 9.229

9.  Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma.

Authors:  Roberto Molinaro; Jonathan O Martinez; Assaf Zinger; Alessandro De Vita; Gianluca Storci; Noemi Arrighetti; Enrica De Rosa; Kelly A Hartman; Nupur Basu; Nima Taghipour; Claudia Corbo; Ennio Tasciotti
Journal:  Biomater Sci       Date:  2019-11-12       Impact factor: 6.843

10.  Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy.

Authors:  Qian Chen; Ligeng Xu; Chao Liang; Chao Wang; Rui Peng; Zhuang Liu
Journal:  Nat Commun       Date:  2016-10-21       Impact factor: 14.919

View more
  5 in total

Review 1.  Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years.

Authors:  Xinyan Hao; Junyong Wu; DaXiong Xiang; Yongyu Yang
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

Review 2.  Bio-interactive nanoarchitectonics with two-dimensional materials and environments.

Authors:  Xuechen Shen; Jingwen Song; Cansu Sevencan; David Tai Leong; Katsuhiko Ariga
Journal:  Sci Technol Adv Mater       Date:  2022-03-30       Impact factor: 8.090

Review 3.  Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.

Authors:  Qi Jiang; Mixue Xie; Ruyin Chen; Feifei Yan; Chanqi Ye; Qiong Li; Shuaishuai Xu; Wei Wu; Yunlu Jia; Peng Shen; Jian Ruan
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

Review 4.  Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment.

Authors:  Xin Yu; Chao Fang; Kun Zhang; Chunxia Su
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

Review 5.  Recent Advances in Immunosafety and Nanoinformatics of Two-Dimensional Materials Applied to Nano-imaging.

Authors:  Gabriela H Da Silva; Lidiane S Franqui; Romana Petry; Marcella T Maia; Leandro C Fonseca; Adalberto Fazzio; Oswaldo L Alves; Diego Stéfani T Martinez
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.